Literature DB >> 18619825

Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis.

Steven D Nathan1, Oksana A Shlobin, Scott D Barnett, Rajeev Saggar, John A Belperio, David J Ross, Shahzad Ahmad, Rajan Saggar, Eric Libre, Joseph P Lynch, David A Zisman.   

Abstract

RATIONALE: n class="Disease">Pulmonary hypertension (PH) commonly complicates the course of patients with idiopathic pulmonary fibrosis (IPF). It has a significant impact on outcomes and is, therefore, important to detect.
OBJECTIVES: We sought to characterize the accuracy and performance characteristics of the right ventricular systolic pressure (RVSP) as estimated by echocardiography (ECHO) alone and in conjunction with physiologic indices in predicting the presence of PH in IPF patients.
METHODS: Cross-sectional study of IPF patients from two large tertiary centers in whom both ECHO and right-heart catheterization (RHC) were available.
MEASUREMENTS AND MAIN RESULTS: There were 110 patients with available ECHOs and RHCs. Estimates of RVSP were reported in 60 of these patients (54.5%) of whom 22 (36.6%) had PH, while 16 of the 50 patients without RVSP estimate (32%) had PH. Twenty-four of 60 (40%) ECHOs accurately reflected the pulmonary arterial systolic pressure as measured by RHC. An optimal RVSP threshold for the screening of PH could not be detected. When assessed in combination with various thresholds of PFT and 6-minute walk test (6MWT) parameters, the performance characteristics of the RVSP were slightly improved.
CONCLUSION: The RVSP is not an accurate test for the assessment of PH in IPF patients. Awareness of the various combinations of threshold values for RVSP with and without PFT and 6MWT might nonetheless assist clinicians in risk stratifying IPF patients for the presence of PH.

Entities:  

Mesh:

Year:  2008        PMID: 18619825      PMCID: PMC2649722          DOI: 10.1016/j.rmed.2008.03.022

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  21 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

4.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.

Authors:  Selim M Arcasoy; Jason D Christie; Victor A Ferrari; Martin St John Sutton; David A Zisman; Nancy P Blumenthal; Alberto Pochettino; Robert M Kotloff
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

5.  Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure.

Authors:  K L Chan; P J Currie; J B Seward; D J Hagler; D D Mair; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

6.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

Authors:  J A Bjoraker; J H Ryu; M K Edwin; J L Myers; H D Tazelaar; D R Schroeder; K P Offord
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

7.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

8.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Hassan F Nadrous; Patricia A Pellikka; Michael J Krowka; Karen L Swanson; Nithima Chaowalit; Paul A Decker; Jay H Ryu
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

9.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

Authors:  Hanno H Leuchte; Claus Neurohr; Rainer Baumgartner; Michael Holzapfel; Wolfgang Giehrl; Michael Vogeser; Jürgen Behr
Journal:  Am J Respir Crit Care Med       Date:  2004-04-15       Impact factor: 21.405

10.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

Authors:  Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2003-06-05       Impact factor: 21.405

View more
  44 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

3.  Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent cohort characterization.

Authors:  Cathryn T Lee; Justin M Oldham
Journal:  Clin Pulm Med       Date:  2017-09

4.  Noninvasive assessment of pulmonary vascular resistance and pressure in patients with congenital heart disease: a new method using M-mode echocardiography.

Authors:  Sumito Kimura; Yayoi Nakahata; Takashi Honda; Hisashi Ando; Shohei Ogata; Kazumasa Akiyama; Yoshito Ogihara; Masahiro Ishii
Journal:  J Echocardiogr       Date:  2011-06-11

5.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

Review 6.  Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

7.  Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease.

Authors:  Myriam Amsallem; David Boulate; Zoe Kooreman; Roham T Zamanian; Guillaume Fadel; Ingela Schnittger; Elie Fadel; Michael V McConnell; Gundeep Dhillon; Olaf Mercier; François Haddad
Journal:  Int J Cardiovasc Imaging       Date:  2017-01-24       Impact factor: 2.357

8.  Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis.

Authors:  Belinda N Rivera-Lebron; Paul R Forfia; Maryl Kreider; James C Lee; John H Holmes; Steven M Kawut
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

9.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

10.  Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment.

Authors:  Heng Duong; Catherine A Bonham
Journal:  Clin Pulm Med       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.